Buy TB-500 10mg

TB-500 is a synthetic research peptide derived from Thymosin Beta-4 (Tβ4), a naturally occurring protein involved in cell migration, tissue repair, and wound healing. Researchers developed TB-500 to investigate the biological functions associated with Thymosin Beta-4 in a stable, laboratory-produced peptide. Today, it remains an investigational compound studied across several areas of regenerative and cellular biology.

Over the past two decades, scientists have investigated TB-500 in in vitro studies and animal models involving tendon and ligament healing, muscle regeneration, angiogenesis, cardiovascular research, corneal repair, and inflammation. These studies have expanded scientific understanding of the peptide, although most published evidence remains preclinical, and well-designed human clinical research is still limited.

If you are looking for TB-500 10mg or searching for a trusted source of research-grade TB-500, Sequora Peptides provides high-purity, third-party tested TB-500 manufactured exclusively for laboratory research purposes.

Detailed Research Overview of TB-500

Since its development, TB-500 has been investigated using cell-based studies, animal models, and a limited number of clinical trials using the naturally occurring peptide from which TB-500 is derived, Thymosin Beta-4. It has been studied for its involvement in wound healing, tissue regeneration, angiogenesis, inflammation, cardiovascular biology, and regenerative medicine. These studies have led to a better understanding of TB-500 from a scientific point of view, but most of the evidence that exists to date is preclinical. Here are the most important points of research in chronological order.

1960s–1990s: Early Research on Thymosin Beta-4

The interest in TB-500’s scientific properties actually started with the discovery of Thymosin Beta-4 (Tβ4) in various human tissues. Initial studies suggested that it regulates the level of the protein actin, which is critical to cell structure and movement. This prompted the researchers to explore the effect of Thymosin Beta-4 on wound healing, tissue repair, and cell migration. Further research resulted in the development of TB-500 as a synthetic peptide that can be used to study the many biological activities in the laboratory.

Angiogenesis and wound healing studies 2000-2010

In the early 2000s, researchers went beyond wound healing and angiogenesis, and began to study the mechanisms underlying these processes. In animal studies, improved cell migration, better blood vessel formation, and quicker tissue remodeling after injury were reported. These results led to the conclusion that TB-500 is a peptide of interest in regenerative biology, and further studies were undertaken to explore musculoskeletal and vascular repair.

2010-2020: Musculoskeletal and Cardiovascular Research.

During this time, research was performed on the application of TB-500 in experimental models of tendon, ligament and muscle injury. It was also used to study its effects in cardiac repair, corneal healing, inflammatory signalling and fibrosis after tissue damage. While some studies had promising results in pre-clinical models, the studies in humans were still quite small.

Expanding Research Applications, 2020 – Present

Research is ongoing on TB-500 in various areas of regenerative research. Current research investigates its role in cell migration, extracellular matrix remodeling, angiogenesis, inflammation, and tissue regeneration. Its biological activity is also being studied in cardiovascular, neurological, and ocular models, which helps to understand its underlying mechanisms and possible applications for research.

Summary of Current Research

Scientists are still exploring TB-500 for various peptide research fields, such as:

• Repair of tendons and ligaments.
• Muscle regeneration
• Wound healing
• Angiogenesis
• Cardiovascular biology
• Corneal repair
• Inflammatory signaling
• Tissue remodeling and fibrosis
• Cell migration
• Regenerative medicine

Research has increased significantly over the last two decades, but TB-500 is still a research peptide. The majority of the published data is from laboratory and animal studies, and further human clinical trials are required to assess its biological activity.

How Does TB-500 Work?

It is not known exactly how TB-500 works. In preliminary experiments, though, the peptide has been shown to affect several biological processes that are related to tissue repair, cell movement, and blood vessel formation, the latter of which is known as angiogenesis. The evidence available is largely from laboratory and animal studies, but not from large-scale clinical trials in humans.

The scientific studies mainly focused on TB-500 for its use in:

• Actin Regulation: Experimental studies suggest that TB-500 may interact with actin, a protein that helps maintain the shape, movement, and organization of tissues.
• Cell Migration: Preclinical studies suggest the peptide can facilitate the migration of fibroblasts, endothelial cells, and other cells that play a role in wound healing towards damaged tissues.
• Angiogenesis: Animal studies have explored TB-500’s potential to support the formation of new blood vessels, an important process in tissue repair and regeneration.
• Inflammatory Response: Laboratory data indicate that TB-500 may affect inflammatory signaling pathways that play a role in the body’s inflammatory response to tissue injury.

The results have sparked great scientific interest, but further clinical studies are required to assess the clinical relevance of these findings in humans.

Preclinical Research

In in vitro studies and animal models, TB-500 has been extensively researched. It has been studied for its biological activity in various fields of regenerative medicine, with most published evidence available being preclinical.

• Tendon and Ligament Research: Animal research has shown that tendon and ligament healing, collagen organization, and healing after injury were improved.
• Muscle Regeneration: TB-500 has been shown to support muscle repair through cell migration in experimental models, which also indicate decreased recovery time following an acute muscle injury.
• Wound Healing: TB-500 has been studied for its ability to promote skin wound healing, regenerate skin tissue, and form healthy granulation tissue.
• Angiogenesis: Preclinical studies suggest that TB-500 may stimulate new blood vessel growth, crucial for supplying oxygen and nutrition to injured tissues.
• Cardiovascular Research: Experimental research has explored TB-500 in models of myocardial injury and cardiac repair, with studies examining its role in tissue regeneration and scar formation. 
• Corneal Repair: TB-500 has been studied in animal corneal injuries, with improvements in epithelial healing and tissue recovery observed.

The results remain relevant to the scientists’ interest in TB-500, but further properly designed, human clinical trials are required to establish its safety, effectiveness, and therapeutic uses.

Human Research

The amount of human research on TB-500 is rather limited, with most of the published research focusing on Thymosin Beta-4 (Tβ4), the natural precursor peptide of TB-500. There is very little direct clinical data about TB-500 itself.

In early clinical and translational research on Thymosin Beta-4, the focus was on wound healing, corneal injuries, and tissue repair. While some of the results were promising, they cannot be applied directly to TB-500, since the structure of both peptides differs.

That is why TB-500 is still considered an investigational research peptide, and more clinical studies should be conducted to learn more about its pharmacology, safety, and possible uses.

Current Regulatory Status

TB-500 is an investigational research peptide and is not approved by the U.S. Food and Drug Administration (FDA) for the diagnosis, treatment, cure, or prevention of any disease. It is sold solely for research use only (RUO) and is not for human consumption.

FAQs

What is TB-500?

TB-500 is a synthetic research peptide that is made from Thymosin Beta-4 (Tβ4). It is a naturally occurring peptide that is involved in cell migration, wound healing, tissue repair, and angiogenesis. Researchers have done studies of TB-500 using laboratory and animal models to investigate its biological activity in wound healing, musculoskeletal research, cardiovascular biology, and regenerative medicine. It is still being investigated as a research peptide and has not yet been approved for any therapeutic use in humans.

What is the difference between TB-500 and Thymosin Beta-4?

Thymosin Beta-4 is a naturally occurring peptide with 43 amino acid residues and can be found throughout the human body. TB-500 is a synthetic peptide that has been designed for research and replicates the same biological functions as Thymosin Beta-4. Though both peptides are related, most of the clinical research available for the two peptides has been published for Thymosin Beta-4.

Is TB-500 FDA approved?

Not at all. The U.S. Food and Drug Administration (FDA) has not approved TB-500 for the treatment, diagnosis, cure, or prevention of any disease or condition.

References

1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: A multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
2. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing through promotion of keratinocyte and endothelial cell migration. FASEB Journal. 1999;13(3):379-386.
3. Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004;432(7016):466-472.
4. Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.
5. Philp D, Goldstein AL, Kleinman HK. Thymosin β4 promotes angiogenesis, wound healing, and tissue regeneration. Annals of the New York Academy of Sciences.
6. Irobi E, Aguda AH, Larsson M, et al. Structural basis of actin sequestration by thymosin-β4: Implications for WH2 proteins. The EMBO Journal. 2004;23(18):3599-3608.
7. Esposito S, Deventer K, Geldof L, et al. Development and validation of a method for detecting TB-500 (Ac-LKKTETQ) in equine plasma by LC-MS/MS. Analytical and Bioanalytical Chemistry.
8. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences. 2026;16(12):6202.
9. National Center for Biotechnology Information (NCBI). PubMed Database.
10. National Center for Biotechnology Information (NCBI). PubMed Central (PMC).
11. U.S. Food and Drug Administration (FDA). Drug and Biological Product Databases.
12. World Anti-Doping Agency (WADA). The Prohibited List.